GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...

GlaxoSmithKline ( (GSK)) has provided an update ... Investor Newsletter GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with ...

More about GlaxoSmithKline GSK is a global biopharmaceutical company dedicated to combining science, technology, and talent to advance healthcare. It has a leading respiratory portfolio and is ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as ... the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.

Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab) – which competes with GlaxoSmithKline's Nucala (mepolizumab) and Teva's Cinqaero ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National ...

London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...